Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Bibhuti Bhoi"'
Autor:
Suresh R. Giri, Bibhuti Bhoi, Chitrang Trivedi, Akshyaya Rath, Rohan Rathod, Anish Sharma, Ramchandra Ranvir, Shekhar Kadam, Kailash Ingale, Hiren Patel, Abraham Nyska, Mukul R. Jain
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-13 (2023)
Abstract Background Saroglitazar is a novel PPAR-α/γ agonist with predominant PPAR-α activity. In various preclinical models, saroglitazar has been shown to prevent & reverse symptoms of NASH. In view of these observations, and the fact that NASH
Externí odkaz:
https://doaj.org/article/20294723c6a8452ea710ad36979e2b91
Publikováno v:
Life Sciences. 162:1-13
Aims Rosiglitazone (RSZ), a PPARγ agonist was potent efficacious insulin sensitizing blockbuster drug for treatment of Type 2 diabetes mellitus (T2DM) but the benefit of PPARγ activation in congestive heart failure (CHF) was controversial. The pres
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef98f55159a6cabb472e6890382d48d6
https://doi.org/10.1016/j.lfs.2016.08.013
https://doi.org/10.1016/j.lfs.2016.08.013
Autor:
Rashmi Ramdhave, Rohan Manubhai. Rathod, Mukul R. Jain, Akshyaya Rath, Bibhuti Bhoi, Chitrang Trivedi, Rajesh Sundar, Brijesh Kumar Srivastava, Ranjit C. Desai, Gautam D Patel, Debdutta Bandyopadhyay, Suresh Giri
Publikováno v:
Diabetes. 67
GPR40 is a G-protein-coupled receptor predominantly expressed in pancreatic β-cells. Agonists of GPR40 are known to stimulate insulin secretion and reduces circulating glucose levels in a glucose-dependent manner. TAK-875, a GPR40 small molecule ago
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::161480e510f5deddde98f14d793f37e4
https://doi.org/10.2337/db18-1194-p
https://doi.org/10.2337/db18-1194-p
Autor:
Akshyaya Rath, Chitrang Trivedi, Bibhuti Bhoi, Suresh Giri, Mukul R. Jain, Rohan Manubhai. Rathod
Publikováno v:
Diabetes. 67
Saroglitazar is a novel dual PPARα/γ agonist that shows significant triglyceride-lowering and insulin-sensitizing effects in animal models and humans. Saroglitazar causes insulin sensitization and increases flux of lipids in adipocytes thereby prev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1297e9b733e89b549f5b40933d4de667
https://doi.org/10.2337/db18-1203-p
https://doi.org/10.2337/db18-1203-p
Autor:
Akshyaya Rath, Hiren Patel, Sib Sankar Roy, Rohan Manubhai. Rathod, Suresh Giri, Bibhuti Bhoi, Ramchandra Ranvir, Shekhar Kadam, Chitrang Trivedi, Eshani Karmakar, Pankaj R. Patel, Walter Wahli, Prabodha Swain, Mukul R. Jain, Nabanita Das
Publikováno v:
Liver international : official journal of the International Association for the Study of the Liver. 38(6)
Background & Aims: Non‐alcoholic fatty liver disease (NAFLD) and non‐alcoholic steatohepatitis (NASH) are common clinico‐pathological conditions that affect millions of patients worldwide. In this study, the efficacy of saroglitazar, a novel PP
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ceeec68bd119b9d6b4df86997b926d3
https://pubmed.ncbi.nlm.nih.gov/29164820
https://pubmed.ncbi.nlm.nih.gov/29164820
Autor:
Chitrang Trivedi, Ramchandra Ranvir, Bibhuti Bhoi, Pankaj R. Patel, Geeta Vanage, Suresh Giri, Purvi Vyas, Mukul R. Jain, Akshyaya Rath
Publikováno v:
Pharmacology Research & Perspectives
Saroglitazar is a novel nonthiazolidinediones (TZD) and nonfibric acid derivative designed to act as dual regulator of lipids and glucose metabolism by activating peroxisome proliferator-activated receptors (PPAR). These studies evaluate the efficacy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2da793b0c257a94736afa60933987ec
https://doi.org/10.1002/prp2.136
https://doi.org/10.1002/prp2.136